메뉴 건너뛰기




Volumn 3, Issue 1, 2011, Pages 25-42

Nanotechnology: A focus on treatment of Tuberculosis

Author keywords

Liposome; Nanotechnology; Non polymeric nanoparticle; Polymeric nanoparticle; Tuberculosis

Indexed keywords

ABRIFAM; ACTIMAX; AETINA; AMIKACIN; AMINOSALICYLIC ACID; CAPASTAT SULPHATE; CAPREOMYCIN; CLARITHROMYCIN; CLATHROMYCIN; CLOFAZIMINE; CYCLODEXTRIN; CYCLOSERINE; DENDRIMER; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LIPOSOME; MOXIFLOXACIN; NANOCARRIER; NANOPARTICLE; NIOSOME; POLYMER; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPRODIN; SOLID LIPID NANOPARTICLE; STREPTOBRETTIN; STREPTOMYCIN; STREPTOMYCIN SULFATE; TERIZIDONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIOMYCIN; BCG VACCINE; GATIFLOXACIN; LINEZOLID; OFLOXACIN; P 824; RIFAMPICIN RIFADIN; SESQUISULFATE AGRISTREP;

EID: 81855185681     PISSN: None     EISSN: 09750215     Source Type: Journal    
DOI: 10.5138/ijdd.2010.0975.0215.03051     Document Type: Review
Times cited : (12)

References (88)
  • 1
    • 79959956767 scopus 로고    scopus 로고
    • Robbins Basic Pathology
    • Saunder Elsevier
    • Kumar Vinay, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology, Saunder Elsevier. 2007;8:516-522.
    • (2007) , vol.8 , pp. 516-522
    • Kumar, V.1    Abbas, A.K.2    Fausto, N.3    Mitchell, R.N.4
  • 5
    • 0037028001 scopus 로고    scopus 로고
    • Clinical practice. Latent tuberculosis infection
    • Jasmer RM, Nahid P, Hopewell PC "Clinical practice. Latent tuberculosis infection".N. Engl. J. Med.2002;347(23):1860-1866.
    • (2002) N. Engl. J. Med. , vol.347 , Issue.23 , pp. 1860-1866
    • Jasmer, R.M.1    Nahid, P.2    Hopewell, P.C.3
  • 6
    • 0004260589 scopus 로고    scopus 로고
    • World Health Organization, Retrieved 12 November 2009. Fact sheet No 104
    • "Tuberculosis". World Health Organization. 2007. Retrieved 12 November 2009. Fact sheet No 104.
    • (2007) Tuberculosis
  • 8
    • 0027471981 scopus 로고
    • Immunopathogenesis of pulmonary tuberculosis
    • Dannenberg AM, Jr. Immunopathogenesis of pulmonary tuberculosis. Hosp Pract 1993;28:51-58.
    • (1993) Hosp Pract , vol.28 , pp. 51-58
    • Dannenberg Jr., A.M.1
  • 10
    • 0003081795 scopus 로고
    • Pathogenesis of tuberculosis
    • In: Reichman LB, Herschfield E, editor, New York: Marcel Dekker, Inc
    • Nardell E. Pathogenesis of tuberculosis. In: Reichman LB, Herschfield E, editor. Lung biology in health and disease. New York: Marcel Dekker, Inc.1993,103-123.
    • (1993) Lung biology in health and disease , pp. 103-123
    • Nardell, E.1
  • 11
    • 0017360746 scopus 로고
    • Monocyte recruitment in tuberculosis and sarcoidosis
    • Schmitt E, Meuret G, Stix L. Monocyte recruitment in tuberculosis and sarcoidosis. Br J Haematol 1977;35:11-17.
    • (1977) Br J Haematol , vol.35 , pp. 11-17
    • Schmitt, E.1    Meuret, G.2    Stix, L.3
  • 12
    • 0004102526 scopus 로고
    • 4th edition, Oxford: Pergmon Press
    • Spencer H. Pathology of the lung, 4th edition. Vol 1. Oxford: Pergmon Press; 1985.
    • (1985) Pathology of the lung , vol.1
    • Spencer, H.1
  • 13
    • 0003970212 scopus 로고
    • Philadelphia: The WB Saunders Co
    • Youmans GP. Tuberculosis. Philadelphia: The WB Saunders Co; 1979.
    • (1979) Tuberculosis
    • Youmans, G.P.1
  • 14
    • 0002675726 scopus 로고
    • Overview of clinical tuberculosis
    • In: Bloom BR, editor, Washington, DC: ASM Press
    • Hopewell PC. Overview of clinical tuberculosis. In: Bloom BR, editor. Tuberculosis: Pathogenesis, protection and control. Washington, DC: ASM Press; 1994. pp 25-46.
    • (1994) Tuberculosis: Pathogenesis, protection and control , pp. 25-46
    • Hopewell, P.C.1
  • 16
    • 0346364896 scopus 로고    scopus 로고
    • Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis
    • Gonzalez OY, Adams G, Teeter LD, Bui TT, Musser JM, Graviss EA. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis 2003;7(12):1178-1185.
    • (2003) Int J Tuberc Lung Dis , vol.7 , Issue.12 , pp. 1178-1185
    • Gonzalez, O.Y.1    Adams, G.2    Teeter, L.D.3    Bui, T.T.4    Musser, J.M.5    Graviss, E.A.6
  • 17
    • 84855201910 scopus 로고    scopus 로고
    • An interesting timeline available on
    • History of TB. An interesting timeline available on http://www.indiachestsociety.org/tb/timeline.asp/.
    • History of TB
  • 18
    • 0042818086 scopus 로고    scopus 로고
    • Tuberculosis in the twenty-first century: The Indian response
    • Deivanayagam CN. Tuberculosis in the twenty-first century: The Indian response. J Indian Med Assoc 2003;101(3):139.
    • (2003) J Indian Med Assoc , vol.101 , Issue.3 , pp. 139
    • Deivanayagam, C.N.1
  • 19
    • 0036089343 scopus 로고    scopus 로고
    • The resurgence of disease: Social and historical perspectives on the 'new' tuberculosis
    • Gandy M, Zumla A. The resurgence of disease: social and historical perspectives on the 'new' tuberculosis. Soc Sci Med 2002;55(3):385-401.
    • (2002) Soc Sci Med , vol.55 , Issue.3 , pp. 385-401
    • Gandy, M.1    Zumla, A.2
  • 21
    • 0042316991 scopus 로고    scopus 로고
    • History of tuberculosis control in Ind
    • Mahadev B, Kumar P. History of tuberculosis control in Ind. J Indian Med Assoc 2003;101(3):142-143.
    • (2003) J Indian Med Assoc , vol.101 , Issue.3 , pp. 142-143
    • Mahadev, B.1    Kumar, P.2
  • 22
    • 1642578221 scopus 로고    scopus 로고
    • Fluoroquinolones in the treatment of tuberculosis
    • Mitchison DA. Fluoroquinolones in the treatment of tuberculosis. Am J Respir Crit Care Med 2004;169:334-335.
    • (2004) Am J Respir Crit Care Med , vol.169 , pp. 334-335
    • Mitchison, D.A.1
  • 23
    • 0006350559 scopus 로고
    • A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid and streptomycin and para-aminosalicylic acid
    • Fox W, Sutherland I. A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid and streptomycin and para-aminosalicylic acid. Q J Med 1956;98:221-243.
    • (1956) Q J Med , vol.98 , pp. 221-243
    • Fox, W.1    Sutherland, I.2
  • 24
    • 2042417395 scopus 로고
    • Antimicrobial therapy of pulmonary tuberculosis
    • McDermott W. Antimicrobial therapy of pulmonary tuberculosis. Bull World Health Organ 1960;23:427-461.
    • (1960) Bull World Health Organ , vol.23 , pp. 427-461
    • McDermott, W.1
  • 25
    • 0026028244 scopus 로고
    • Controlled trial of 2, 4 and 6 months of pyrazinamide, in three-timesweekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide
    • Hong Kong Chest Service/British Medical Research Council
    • Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinamide, in three-timesweekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Am Rev Respir Dis 1991;143:700-706.
    • (1991) Am Rev Respir Dis , vol.143 , pp. 700-706
  • 27
    • 61849153021 scopus 로고    scopus 로고
    • Impact of nanotechnology on drug delivery
    • Farokhzad OC, Langer R., Impact of nanotechnology on drug delivery. ACS Nano. 3(1), 2009,16-20.
    • (2009) ACS Nano , vol.3 , Issue.1 , pp. 16-20
    • Farokhzad, O.C.1    Langer, R.2
  • 30
    • 33947221977 scopus 로고    scopus 로고
    • A systematic review of rapid diagnostic tests for the detection of tuberculosis infection
    • Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection, Health. Technol. Assess. 2007;11:1-178.
    • (2007) Health Technol. Assess. , vol.11 , pp. 1-178
    • Dinnes, J.1    Deeks, J.2    Kunst, H.3    Gibson, A.4    Cummins, E.5    Waugh, N.6
  • 31
    • 58149489663 scopus 로고    scopus 로고
    • Diagnosis of latent tuberculosis: Can we do better?
    • Al-Orainey I. Diagnosis of latent tuberculosis: can we do better? Ann. Thorac. Med. 2009;4: 5-9.
    • (2009) Ann. Thorac. Med. , vol.4 , pp. 5-9
    • Al-Orainey, I.1
  • 32
    • 0038674868 scopus 로고    scopus 로고
    • About dendrimers: Structure, physical properties, and applications
    • Bosman AW, Janssen HM, Meijer EW. About dendrimers: structure, physical properties, and applications. Chem Rev 1999;99:1665-88.
    • (1999) Chem Rev , vol.99 , pp. 1665-1688
    • Bosman, A.W.1    Janssen, H.M.2    Meijer, E.W.3
  • 33
    • 33750127627 scopus 로고    scopus 로고
    • Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers
    • Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers, J. Drug Target. 2006;14:546-556.
    • (2006) J. Drug Target. , vol.14 , pp. 546-556
    • Kumar, P.V.1    Asthana, A.2    Dutta, T.3    Jain, N.K.4
  • 34
    • 33846115676 scopus 로고    scopus 로고
    • PEGylated dendritic architecture for development of a prolonged drug delivery system of an antitubercular drug
    • Kumar PV, Agashe H, Dutta T, Jain NK. PEGylated dendritic architecture for development of a prolonged drug delivery system of an antitubercular drug, Curr. Drug Deliv. 2007;4:11-19.
    • (2007) Curr. Drug Deliv. , vol.4 , pp. 11-19
    • Kumar, P.V.1    Agashe, H.2    Dutta, T.3    Jain, N.K.4
  • 35
    • 0022592084 scopus 로고
    • Hydroxypropyl-β-cyclodextrin: Preparation and characterization; effects on solubility of drugs
    • Pitha J, Milecki J, Fales H, Pannell L, Uekama K. Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs, International Journal of Pharmaceutics. 1986;29(1):73-82.
    • (1986) International Journal of Pharmaceutics , vol.29 , Issue.1 , pp. 73-82
    • Pitha, J.1    Milecki, J.2    Fales, H.3    Pannell, L.4    Uekama, K.5
  • 39
    • 3843097202 scopus 로고    scopus 로고
    • Classification of orally administered drug on the World Health Organization model list of essential medicines according to the Biopharmaceutics Classification System
    • Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drug on the World Health Organization model list of essential medicines according to the Biopharmaceutics Classification System, Eur. J. Pharm. Biopharm. 2004;58:265-278.
    • (2004) Eur. J. Pharm. Biopharm. , vol.58 , pp. 265-278
    • Lindenberg, M.1    Kopp, S.2    Dressman, J.B.3
  • 40
    • 19544364888 scopus 로고    scopus 로고
    • Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models
    • Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models, Antimicrob. Agents Chemother. 2005;49: 2294-2301.
    • (2005) Antimicrob. Agents Chemother. , vol.49 , pp. 2294-2301
    • Lenaerts, A.J.1    Gruppo, V.2    Marietta, K.S.3    Johnson, C.M.4    Driscoll, D.K.5    Tompkins, N.M.6
  • 42
    • 0035937592 scopus 로고    scopus 로고
    • Block copolymer micelles for drug delivery: Design, characterization and biological significance
    • Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance, Adv. Drug Deliv. Rev. 2001;47:113-131.
    • (2001) Adv. Drug Deliv. Rev. , vol.47 , pp. 113-131
    • Kataoka, K.1    Harada, A.2    Nagasaki, Y.3
  • 43
    • 33751512735 scopus 로고    scopus 로고
    • Polymeric micelles for drug delivery
    • Croy SR, Kwon GS. Polymeric micelles for drug delivery, Curr. Pharm. Des. 2006;12:4669-4684.
    • (2006) Curr. Pharm. Des. , vol.12 , pp. 4669-4684
    • Croy, S.R.1    Kwon, G.S.2
  • 44
    • 34248577169 scopus 로고    scopus 로고
    • Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs
    • Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs, Eur. J. Pharm. Biopharm. 2007;66:303-317.
    • (2007) Eur. J. Pharm. Biopharm. , vol.66 , pp. 303-317
    • Chiappetta, D.A.1    Sosnik, A.2
  • 47
    • 84898695652 scopus 로고    scopus 로고
    • Preparation of polymeric micelles for use as carriers of tuberculostatic drugs
    • Silva M, Ferreira EI, Leite CQF, Sato DN. Preparation of polymeric micelles for use as carriers of tuberculostatic drugs, Trop. J. Pharm. Res.2007;6:815-824.
    • Trop. J. Pharm. Res , vol.2007 , pp. 6
    • Silva, M.1    Ferreira, E.I.2    Leite, C.Q.F.3    Sato, D.N.4
  • 48
    • 43849093356 scopus 로고    scopus 로고
    • Monolayers of the lipid derivatives of isoniazid atbthe air/water interface and the formation of self-assembled nanostructures in water
    • Jin Y, Chen S, Xin R, Zhou Y. Monolayers of the lipid derivatives of isoniazid atbthe air/water interface and the formation of self-assembled nanostructures in water, Colloids Surf., B Biointerfaces 2008;64:229-235.
    • (2008) Colloids Surf., B Biointerfaces , vol.64 , pp. 229-235
    • Jin, Y.1    Chen, S.2    Xin, R.3    Zhou, Y.4
  • 50
    • 15544362279 scopus 로고    scopus 로고
    • Polymeric particulates to improve oral bioavailability of peptide drugs
    • Delie F, Blanco-Prieto MJ. Polymeric particulates to improve oral bioavailability of peptide drugs, Molecules 2005;10:65-80.
    • (2005) Molecules , vol.10 , pp. 65-80
    • Delie, F.1    Blanco-Prieto, M.J.2
  • 51
    • 0028837083 scopus 로고    scopus 로고
    • Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery
    • Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery, Int. J. Pharm.1995;116:1-9.
    • Int. J. Pharm , vol.1995 , pp. 116
    • Brannon-Peppas, L.1
  • 52
    • 28844488494 scopus 로고    scopus 로고
    • Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
    • Owens TE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm. 2006;307:93-102.
    • (2006) Int. J. Pharm. , vol.307 , pp. 93-102
    • Owens, T.E.1    Peppas, N.A.2
  • 53
    • 0034559933 scopus 로고    scopus 로고
    • Nanoparticles as antituberculosis drugs carriers: Effect on activity against My cobacterium tuberculosis in human monocyte-derived macrophages
    • Anisimova YV, Gelperina SI, Peloquin CA, Heifets LB. Nanoparticles as antituberculosis drugs carriers: effect on activity against My cobacterium tuberculosis in human monocyte-derived macrophages, J. Nanopart. Res. 2000; 2:165-171.
    • (2000) J. Nanopart. Res , vol.2 , pp. 165-171
    • Anisimova, Y.V.1    Gelperina, S.I.2    Peloquin, C.A.3    Heifets, L.B.4
  • 54
    • 36048983390 scopus 로고    scopus 로고
    • Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis
    • Kisich KO, Gelperina SI, Higgins MP, Wilson S, Shipulo E, Oganesyan E. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis, Int. J. Pharm. 2007;345:154-162.
    • (2007) Int. J. Pharm. , vol.345 , pp. 154-162
    • Kisich, K.O.1    Gelperina, S.I.2    Higgins, M.P.3    Wilson, S.4    Shipulo, E.5    Oganesyan, E.6
  • 56
    • 0344010111 scopus 로고    scopus 로고
    • Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis
    • Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis, Tuberculosis 2003;83:373-378.
    • (2003) Tuberculosis , vol.83 , pp. 373-378
    • Pandey, R.1    Zahoor, A.2    Sharma, S.3    Khuller, G.K.4
  • 57
    • 33746623370 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic behavior of antitubercular drugs encapsulated in alginate nanoparticles at two doses
    • Zahoor A, Pandey R, Sharma S, Khuller GK. Pharmacokinetic and pharmacodynamic behavior of antitubercular drugs encapsulated in alginate nanoparticles at two doses, Int. J. Antimicrob. Agents 2006;27:409-416.
    • (2006) Int. J. Antimicrob. Agents , vol.27 , pp. 409-416
    • Zahoor, A.1    Pandey, R.2    Sharma, S.3    Khuller, G.K.4
  • 58
    • 0016404438 scopus 로고
    • Drug carrier potential of liposomes in cancer chemotherapy
    • Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug carrier potential of liposomes in cancer chemotherapy, Lancet 1974;1:1313-1316.
    • (1974) Lancet , vol.1 , pp. 1313-1316
    • Gregoriadis, G.1    Wills, E.J.2    Swain, C.P.3    Tavill, A.S.4
  • 59
    • 0025282170 scopus 로고
    • Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice
    • Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice, Antimicrob. Agents Chemother. 1990;34:967-970.
    • (1990) Antimicrob. Agents Chemother. , vol.34 , pp. 967-970
    • Klemens, S.P.1    Cynamon, M.H.2    Swenson, C.E.3    Ginsberg, R.S.4
  • 60
    • 0031943679 scopus 로고    scopus 로고
    • Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection
    • Leitzke S, Bucke W, Borner K, Muller R, Hahn H, Ehlers S. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection, Antimicrob. Agents Chemother. 1998;42: 459-461.
    • (1998) Antimicrob. Agents Chemother. , vol.42 , pp. 459-461
    • Leitzke, S.1    Bucke, W.2    Borner, K.3    Muller, R.4    Hahn, H.5    Ehlers, S.6
  • 61
    • 0029129973 scopus 로고
    • Formulation and efficacy of liposomeencapsulated antibiotics for therapy of intracellular Mycobacterium avium infection
    • Oh YK, Nix DE, Straubinger RM. Formulation and efficacy of liposomeencapsulated antibiotics for therapy of intracellular Mycobacterium avium infection, Antimicrob. Agents Chemother. 1995;39:2104-2111.
    • (1995) Antimicrob Agents Chemother. , vol.39 , pp. 2104-2111
    • Oh, Y.K.1    Nix, D.E.2    Straubinger, R.M.3
  • 62
    • 0029910034 scopus 로고    scopus 로고
    • Treatment of intracellular Mycobacterium avium complex infection by free and liposomeencapsulated sparfloxacin
    • Duzgunes N, Flasher D, Reddy MV, Luna-Herrera J, Gangadharam PR. Treatment of intracellular Mycobacterium avium complex infection by free and liposomeencapsulated sparfloxacin, Antimicrob. Agents Chemother. 1996;40:2618-2621.
    • (1996) Antimicrob Agents Chemother. , vol.40 , pp. 2618-2621
    • Duzgunes, N.1    Flasher, D.2    Reddy, M.V.3    Luna-Herrera, J.4    Gangadharam, P.R.5
  • 63
    • 0030890637 scopus 로고    scopus 로고
    • Lung specific liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice
    • Deol P, Khuller GK. Lung specific liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice, Biochem. Biophys. Acta 1997;1334:161-172.
    • (1997) Biochem. Biophys. Acta , vol.1334 , pp. 161-172
    • Deol, P.1    Khuller, G.K.2
  • 64
    • 0030918970 scopus 로고    scopus 로고
    • Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice
    • Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice, Antimicrob. Agents Chemother. 1997;41:1211-1214.
    • (1997) Antimicrob Agents Chemother. , vol.41 , pp. 1211-1214
    • Deol, P.1    Khuller, G.K.2    Joshi, K.3
  • 65
    • 0027368832 scopus 로고    scopus 로고
    • In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and Mycobacterium tuberculosis
    • Mehta RT, Keyhani A, McQueen TJ, Rosenbaum B, Rolston KV, Tarrand JJ. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and Mycobacterium tuberculosis, Antimicrob. Agents Chemother. 1999;37:2584-2587.
    • (1999) Antimicrob Agents Chemother. , vol.37 , pp. 2584-2587
    • Mehta, R.T.1    Keyhani, A.2    McQueen, T.J.3    Rosenbaum, B.4    Rolston, K.V.5    Tarrand, J.J.6
  • 67
    • 33846193666 scopus 로고    scopus 로고
    • Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis
    • El-Ridy MS, Mostafa DM, Shehab A, E.A. Nasr, S.A. El-Alim, Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis, Int. J. Pharm. 2007;330:82-88.
    • (2007) Int. J. Pharm. , vol.330 , pp. 82-88
    • El-Ridy, M.S.1    Mostafa, D.M.2    Shehab, A.3    Nasr, E.A.4    El-Alim, S.A.5
  • 69
    • 39149118304 scopus 로고    scopus 로고
    • Advances in lipid nanodispersions for parenteral drug delivery and targeting
    • Constantinides PP, Chaubal MV, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting, Adv. Drug Deliv. Rev. 2008;60:757-767.
    • (2008) Adv. Drug Deliv. Rev. , vol.60 , pp. 757-767
    • Constantinides, P.P.1    Chaubal, M.V.2    Shorr, R.3
  • 71
    • 56749107618 scopus 로고    scopus 로고
    • Potential of nanoemulsions for intravenous delivery of rifampicin
    • Ahmed M, Ramadan W, Rambhu D, Shakeel F. Potential of nanoemulsions for intravenous delivery of rifampicin, Pharmazie 2008;63:806-811.
    • (2008) Pharmazie , vol.63 , pp. 806-811
    • Ahmed, M.1    Ramadan, W.2    Rambhu, D.3    Shakeel, F.4
  • 72
    • 4544383493 scopus 로고    scopus 로고
    • Nanosuspensions in drug delivery
    • Rabinow BE. Nanosuspensions in drug delivery, Nat. Rev. Drug Discov. 2004;3:785-796.
    • (2004) Nat Rev. Drug Discov. , vol.3 , pp. 785-796
    • Rabinow, B.E.1
  • 73
    • 0033965872 scopus 로고    scopus 로고
    • Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection
    • Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection, J. Antimicrob. Chemother. 2000;45:7783.
    • (2000) J. Antimicrob. Chemother. , vol.45 , pp. 7783
    • Peters, K.1    Leitzke, S.2    Diederichs, J.E.3    Borner, K.4    Hahn, H.5    Müller, R.H.6
  • 74
    • 0037190027 scopus 로고    scopus 로고
    • Rifampicin microparticles production by supercritical antisolvent precipitation
    • Reverchon E, De Marco I, Della Porta G. Rifampicin microparticles production by supercritical antisolvent precipitation, Int. J. Pharm.2002;243:83-91.
    • Int. J. Pharm , vol.2002 , pp. 243
    • Reverchon, E.1    de Marco, I.2    Della Porta, G.3
  • 75
    • 0037678925 scopus 로고    scopus 로고
    • Micronization of antibiotics by supercritical assisted atomization
    • Reverchon E, Della Porta G. Micronization of antibiotics by supercritical assisted atomization, J. Supercrit. Fluids 2003;26:243-252.
    • (2003) J. Supercrit. Fluids , vol.26 , pp. 243-252
    • Reverchon, E.1    Della Porta, G.2
  • 77
    • 0029052419 scopus 로고
    • Preparation and characterization of niosomes containing rifampicin for lung targeting
    • Jain CP, Vyas SP. Preparation and characterization of niosomes containing rifampicin for lung targeting, J. Microencapsul 1995;12:401-407.
    • (1995) J. Microencapsul , vol.12 , pp. 401-407
    • Jain, C.P.1    Vyas, S.P.2
  • 78
    • 33846162000 scopus 로고    scopus 로고
    • Niosomal system for delivery of rifampicin to lymphatics
    • Jain CP, Vyas SP, Dixit VK. Niosomal system for delivery of rifampicin to lymphatics, Indian J. Pharm. Sci.2006;68:575-578.
    • Indian J. Pharm. Sci , vol.2006 , pp. 68
    • Jain, C.P.1    Vyas, S.P.2    Dixit, V.K.3
  • 79
    • 1942505838 scopus 로고    scopus 로고
    • Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat
    • Mullaicharam AR, Murthy RSR. Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat, J. Drug Deliv. Sci. Technol. 2004;14:99-104.
    • (2004) J. Drug Deliv. Sci. Technol. , vol.14 , pp. 99-104
    • Mullaicharam, A.R.1    Murthy, R.S.R.2
  • 80
    • 1642460578 scopus 로고    scopus 로고
    • Nanosuspension as the most promising approach in nanoperticulate drug delivery system
    • Rao GC, Kumar MS, Mathivanon N, Rao ME. Nanosuspension as the most promising approach in nanoperticulate drug delivery system, pharmazie. 2004;59:5.
    • (2004) Pharmazie. , vol.59 , pp. 5
    • Rao, G.C.1    Kumar, M.S.2    Mathivanon, N.3    Rao, M.E.4
  • 83
    • 17444377960 scopus 로고    scopus 로고
    • Antitubercular inhaled therapy: Opportunities, progress and challenges
    • Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrobial Chemotherapy 2005;55:430-435.
    • (2005) J Antimicrobial Chemotherapy , vol.55 , pp. 430-435
    • Pandey, R.1    Khuller, G.K.2
  • 84
    • 0347519282 scopus 로고    scopus 로고
    • Poly (DL-lactide-co glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
    • Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-986.
    • (2003) J Antimicrob Chemother , vol.52 , pp. 981-986
    • Pandey, R.1    Sharma, A.2    Zahoor, A.3    Sharma, S.4    Khuller, G.K.5    Prasad, B.6
  • 85
    • 6344277290 scopus 로고    scopus 로고
    • Lectin-functionalized poly (lactideco-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis
    • Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactideco-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54:761-766.
    • (2004) J Antimicrob Chemother , vol.54 , pp. 761-766
    • Sharma, A.1    Sharma, S.2    Khuller, G.K.3
  • 86
    • 20444385102 scopus 로고    scopus 로고
    • Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis
    • Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85:227-234.
    • (2005) Tuberculosis (Edinb) , vol.85 , pp. 227-234
    • Pandey, R.1    Khuller, G.K.2
  • 87
    • 3042586026 scopus 로고    scopus 로고
    • Physical chemical considerations of lipid-based oral drug delivery: Solid lipid nanoparticles
    • Bummer PM. Physical chemical considerations of lipid-based oral drug delivery: solid lipid nanoparticles. Crit Rev Ther Drug Carrier Syst 2004;21:1-20.
    • (2004) Crit Rev Ther Drug Carrier Syst , vol.21 , pp. 1-20
    • Bummer, P.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.